<DOC>
	<DOCNO>NCT00513409</DOCNO>
	<brief_summary>This booster study 2 group healthy child le 3 year old measure reactogenicity , safety immunogenicity GSK Biologicals ' pneumococcal conjugate vaccine , give booster two-dose catch-up vaccination . This protocol post deal objectives outcome measure booster phase . The objective outcome measure primary phase present separate protocol posting ( NCT number = NCT00338351 ) .</brief_summary>
	<brief_title>Assess Reacto- Immunogenicity Pneumococcal Conjugate Vaccine When Given Booster 2 Dose Catch Schedule</brief_title>
	<detailed_description>The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</detailed_description>
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male female , include , 1821 month age time vaccination . Subjects previously participate primary study receive 3 dos study control vaccine primary study . Subjects investigator believe parents/guardians comply requirement protocol . Written inform consent obtain parent guardian subject . Free obvious health problem establish medical history clinical examination enter study . Use investigational nonregistered drug vaccine study vaccine ( ) within 30 day precede booster dos study vaccine , plan use study period ( active phase extend safety followup ) . Planned administration/ administration vaccine foreseen study protocol period start one month ( 30 day ) booster dos vaccine ( ) active phase study ( followup visit ( Visit 3 ) ) . History allergic disease reaction likely exacerbate component vaccine . History seizure ( subject single , uncomplicated febrile convulsion past include ) progressive neurological disease . Acute disease time enrolment . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within 6 month prior booster dos study vaccine . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination . A family history congenital hereditary immunodeficiency . Major congenital defect serious chronic illness . Administration immunoglobulins and/or blood product within last 3 month prior booster followup vaccination plan administration active phase study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>21 Months</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Immunogenicity</keyword>
	<keyword>Pneumococcal disease</keyword>
	<keyword>Safety</keyword>
	<keyword>Booster vaccination</keyword>
	<keyword>Pneumococcal vaccine</keyword>
</DOC>